RT Journal Article
SR Electronic
T1 Antitumor Efficacy of Vaccinia Virus-modified Tumor Cell Vaccine
JF Cancer Research
JO Cancer Res
FD American Association for Cancer Research
SP 6915
OP 6918
VO 50
IS 21
A1 Ito, Tetsuya
A1 Wang, Da-Qing
A1 Maru, Morimasa
A1 Nakajima, Kazuhiro
A1 Kato, Shiro
A1 Kurimura, Takashi
A1 Wakamiya, Nobutaka
YR 1990
UL http://cancerres.aacrjournals.org/content/50/21/6915.abstract
AB The antitumor efficacies of vaccinia virus-modified tumor cell vaccines were examined in murine syngeneic MH134 and X5563 tumor cells. UV-inactivated vaccinia virus was inoculated i.p. into C3H/HeN mice that had received whole body X-irradiation at 150 rads. After 3 weeks, the vaccines were administered i.p. 3 times at weekly intervals. One week after the last injection, mice were challenged i.p. with various doses of syngeneic MH134 or X5563 viable tumor cells. Four methods were used for preparing tumor cell vaccines: X-ray irradiation; fixation with paraformaldehyde for 1 h or 3 months; and purification of the membrane fraction. All four vaccines were effective, but the former two vaccines were the most effective. A mixture of the membrane fraction of untreated tumor cells and UV-inactivated vaccinia virus also had an antitumor effect. These results indicate that vaccine with the complete cell structure is the most effective. The membrane fraction of UV-inactivated vaccinia virus-absorbed tumor cells was also effective. UV-inactivated vaccinia virus can react with not only intact tumor cells but also the purified membrane fraction of tumor cells and augment antitumor activity. ©1990 American Association for Cancer Research.